Objectives:

To describe and analyze the results of the development of the “Information and communications technology adapted to remote pharmaceutical care” (TICAFAN, by its Spanish acronym) project and confirm its validity to provide pharmaceutical care to chronic myelogenous leukemia patients.

Methods:

Before and after study of a modified pharmaceutical care model. The course of the disease, pharmaceutical interventions, treatment adherence, and number of home deliveries and their incidents were analyzed from February 1, 2014 to October 31, 2016. A satisfaction survey was conducted in May 2015.

Results:

Twenty one patients were included in the program until October 31, 2016. The mean age at the time of inclusion was 55 years (SD 17). There were 470 home deliveries, with an 80% (SD 15) reduction in the trips to the hospital. There were 2 incidents owing to the fact that the patients did not remember the shipment date. Forty nine pharmaceutical interventions were registered and 30 on-demand inquiries were answered, apart from the scheduled monthly consultations. This meant a greater number of interventions than in a previous period. There were no differences in adherence before and after the inclusion in the program. Response was maintained in 9 patients, improved in 9 and worsened, but recovered afterwards, in 3 patients. Patients gave the project a score of 9.7 (SD 0.6) out of 10.

Conclusions:

The TICAFAN project has managed to keep providing pharmaceutical care as well as to maintain adherence and treatment response, reducing hospital visits for drug collection.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )